.gif)
Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. ("Laurel").
The acquisition of Ocata represents the coming together of two companies with significant accomplishments and a shared commitment to development innovative therapies that address the unmet medical needs of patients suffering from severe ophthalmic diseases.
“We highly value Ocata’s R&D capabilities, including its world-leading researchers in cell therapy,” Astellas CEO Yoshihiko Hatanaka said in a statement. “We are confident we will turn innovative science into value for patients.”
Ocata CEO Paul Wotton said, “I am impressed by the vision and commitment of Astellas,” adding that the Japanese company’s resources would help bring his company’s cell therapies to market.
Subscribe to PharmaTutor News Alerts by Email >>
